Meetings 

The Company is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company has two FDA approved products: DUEXIS® and RAYOS®.  DUEXIS®s is a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill.  DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (“RA”) and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. In June 2012, the Company began expanding its commercial organization and expects to almost double its original field force size by the end of the third quarter of 2012, to approximately 150 field sales representatives. Also in June 2012, the Company engaged Mallinckrodt LLC, the pharmaceutical business of Covidien plc, on a non-exclusive basis to co-promote DUEXIS in the U.S. and entered into an exclusive collaboration, license and supply agreement with Grünenthal S.A. for the potential commercialization of DUEXIS in Latin America.

The Company’s second product, RAYOS®, known as LODOTRA® outside the U.S., is a proprietary delayed release formulation of low-dose prednisone that is currently marketed in Europe by its distribution partner, Mundipharma International Corporation Limited (“Mundipharma”), for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. In addition, the Company has granted to Mundipharma commercialization rights to LODOTRA in Asia and Latin America. On July 26, 2012, the FDA approved RAYOS for the treatment of a broad range of diseases, including RA, polymyalgia rheumatica (“PMR”), psoriatic arthritis (“PsA”), ankylosing spondylitis (“AS”), asthma and chronic obstructive pulmonary disease (“COPD”). The Company anticipates the launch of RAYOS in the United States in the fourth quarter of 2012. The Company’s strategy is to commercialize its products in the U.S. and to enter into licensing or additional distribution agreements for commercialization of its products outside the U.S.

ImmunGene is leveraging promising science to empower therapeutic antibodies with immune molecules.  These molecules are highly optimized for dramatic efficacy and a superior safety profile. 

Our technology allows us to genetically engineer cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.  ImmunGene has several antibody molecules genetically engineered with interferon for following indications:

Non-Hodgkins lymphoma

Leukemia

Multiple myeloma

Melanoma

Renal cancer

Prostate cancer

Breast Cancer

Jaleva Pharmaceuticals is a company focused on the improved delivery of active ingredients to the skin or mucosa.  We achieve this with our Patented Resin technology, and do so topically, and transmucosally.  The core of our Delivery is fast acting, and long lasting delivery of API's.

We currently have three products ready for license.  

1. A Surgical Prep product to compete with Chloraprep.

2. A Topical Pain Relief Spray, for two times a day use.

3. An NRT Trans-buccal product, quick acting, mimicking the craving reduction of a cigarette.

We have an array of other products in our development pipeline.  

JRX Biotech is focused on (1) pain management and (2) dermatology applications.  We are a post revenue specialty biochemistry technology company.

We develop topical products using our patented delivery system platform (formfactors: liquid solutions, serums, lotions, creams, sprays).

DermX Megasphere Delivery System -- a dermal/transdermal delivery system technology platform that has been independently proven to allow high payloads of large molecular weight molecules to passively penetrate into and through human skin.

DermX Features / Benefits:

  --Passive, topical solution

  --Patented

  --Proven (Franz Cell and in vivo)

  --High payloads delivered (>20% of the applied dose penetrating)

  --Large molecules delivered (>11kD)

  --No irritation

We are looking to:

  (1) Co-develop our lead topical pain relief patented product (first-in-class).

  (2) Co-develop our pipeline of patented topical pain relief products.

  (3) Out-license our platform delivery system technology.

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.

Today, the portfolio consists of 35 projects, of which 14 are pharmaceuticals in clinical development, 7 in phase I and 7 in phase II

In the active portfolio, Karolinska Development has four projects in oncology, whereof three in clinical development, four clinical development programs in skin disease and wound healing, three projects in women’s health, two in infection, two in CVD, CNS and inflammation respectively and one in opthalmology. Furthermore, 10 technology programs in the areas of implants, diagnostics, formulation and medical equipment. Several are open for licensing and co-development discussions.

We are also looking for breakthrough investment opportunities in the areas of Life Sciences (pharma/biotech, medtech)